TIDMOXB
RNS Number : 7269O
Oxford Biomedica PLC
04 October 2023
Grant of options
London, UK - 04 October 2023: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB) announces that on 04
October 2023 nil-cost share options over ordinary shares of 50
pence each in the Company were granted under the Oxford Biomedica
2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long
Term Incentive Plan ("LTIP").
2023 LTIP and 2022 DBP Awards
Name of individual Title Number Number of Total shares Percentage
of shares shares subject over which of current
subject to the 2023 options issued share
to the LTIP award now held capital
2022 DBP under option
award
Chief Executive
Frank Mathias Officer - 323,178 323,178 0.334%
------------------- ----------- ---------------- ------------- --------------
Chief Financial
Stuart Paynter Officer 63,869 142,469 538,211 0.556%
------------------- ----------- ---------------- ------------- --------------
Chief Commercial
Sebastien Ribault Officer 66,903 66,903 0.069%
------------------- ----------- ---------------- ------------- --------------
Site Head US
Mark Caswell Operations 74,172 74,172 0.077%
------------------- ----------- ---------------- ------------- --------------
Chief People
Lisa James Officer 15,887 39,670 99,989 0.103%
------------------- ----------- ---------------- ------------- --------------
Chief Technical
James Miskin Officer 32,189 56,262 215,035 0.222%
------------------- ----------- ---------------- ------------- --------------
Chief Scientific
Kyriacos Mitrophanous Officer 35,256 57,906 277,856 0.287%
------------------- ----------- ---------------- ------------- --------------
Madduri Ravi Chief Medical
Rao Officer 21,129 50,135 131,400 0.136%
------------------- ----------- ---------------- ------------- --------------
Chief Information
Officer and
Matthew Treagus Chief of Staff 32,468 54,433 143,648 0.148%
------------------- ----------- ---------------- ------------- --------------
Natalie Walter General Counsel 27,897 48,069 167,244 0.173%
------------------- ----------- ---------------- ------------- --------------
Under the terms of the DBP plan, the DBP awards will become
exercisable as to one third of the shares subject to each award on
each of the first three anniversaries of the grant date.
In line with best practice and current investor guidance the
quantum of the 2023 LTIP to Frank Mathias was scaled back from 200%
of salary to 160% of salary and for Stuart Paynter the quantum of
the 2023 LTIP was scaled back by 30% from 175% of salary to 122.5%
of salary. The quantum of 2023 LTIP granted to other new members of
SET was scaled back by 20%, all other members of the set had their
awards scaled back by 30%
The LTIP awards are subject to performance conditions. As set
out in the 2022 Directors' Remuneration Report, the performance
condition is based on TSR (40% of the award, assessed over the
three years from grant); revenue growth (40% of the award, assessed
over financial years 2023, 2024 and 2025) and strategic milestones
(20% of the award). Details of the measures are included in the
2022 Directors' Remuneration Report, other than as regards the
strategic milestones, which are commercially sensitive and will be
disclosed in due course.
The LTIP awards granted to Frank Mathias and Stuart Paynter will
"vest" following the assessment of the performance condition, but
will only be "released" so that they can be exercised following the
end of a further two year holding period. The 2023 awards granted
to other participants will vest and be released following the
assessment of the performance condition.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Frank Mathias
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Executive Officer
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 323,178
--------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 323,178 shares
in total
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Stuart Paynter
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 142,469
--------
2022 DBP Award
Price Volume
Nil 63,869
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 206,338 shares
in total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Sebastien Ribault
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Commercial Officer
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 66,903
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 66,903 shares in
total
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Mark Caswell
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Site Head of US Operations
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 74,172
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 74,172 shares in
total
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Lisa James
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief People Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 39,670
-------
2022 DBP Award
Price Volume
Nil 15,887
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 55,557 shares in
total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name James Miskin
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Technical Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 56,262
-------
2022 DBP Award
Price Volume
Nil 32,189
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 88,451 shares in
total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 57,906
-------
2022 DBP Award
Price Volume
Nil 35,256
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 93,162 shares in
total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Madduri Rao
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Medical Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 50,135
-------
2022 DBP Award
Price Volume
Nil 21,129
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 71,264 shares in
total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Matthew Treagus
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Information Officer and Chief
of Staff
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 54,433
-------
2022 DBP Award
Price Volume
Nil 32,468
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 86,901 shares in
total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Natalie Walter
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status General Counsel
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument ISIN: GB00BDFBVT43
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2023 LTIP Award
Price Volume
Nil 48,069
-------
2022 DBP Award
Price Volume
Nil 27,897
-------
----------------------------- ------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 75,966 shares in
total
* Price N/A
----------------------------- ------------------------------------------------
e) Date of the transaction 2023-10-04
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell
and gene therapy CDMO with a mission to enable its clients to
deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and near
Boston, MA, US. Learn more at www.oxb.com , www.oxbsolutions.com ,
and follow us on LinkedIn
and YouTube .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGZMGGVDNGFZM
(END) Dow Jones Newswires
October 04, 2023 12:09 ET (16:09 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
